Sinogene Snares ￥10M in Series B1 Funding Round

According to VCBeat, Sinogene, a leading pet cloning company, has recently completed Series B1 funding round of tens of millions, led by Shunqi Fund with participation from Xinuo Hengtong. Previously, Sinogene got investment from PEOPLE's Insurance & Qidi Fund in the Pre-A round in December 2017 and investment from CCBI Health Care Growth Fund in Series A round in September 2018. 

With the transformation and commercialization of scientific and technological achievements of Sinogene, proceeds from the latest round will be mainly used for long-term development, expansion of the pet market, achievement transformation, and industrialization.

Sinogene is the first commercial pet cloning company in China with completely independent intellectual property rights. The company offers industry-leading genetic preservation and cloning technology for pet cloning. Its team includes leading scientists, doctors, and veterinary specialists. With intensive scientifically based management, Sinogene made a positive impact on so many families' lives by delivering a replica of their pets.

Sinogene created the animal cloning technology platform of many species (dogs, cats, horses, pigs, cows) and animal genes editing technology platform. It has developed the original series of kennel disease model from gene editing, established a genetic disease cell bank, and carried out preclinical researches of animal models created by genome editing to advance biological medicine R&D and provide ideal animal models and supporting platform for the study of human disease mechanism, drug screening, and drug evaluation.

In 2019, Sinogene has been deeply engaged in the pet market and promoted its business of pet cloning, genetic testing, cell preservation, and others. Research services such as the customized animal modeling and experiments of animal models have been successively launched, which have gradually been recognized by the market. Sinogene's yearly revenue has reached tens of millions in 2019.

Shunqi Fund takes new technology as its main direction of investment, focused on medical devices and other fields. The company works closely with the Beijing Equity Exchange Center and science and technology parks to help incubate medical device startups.

CCBI Health Care Growth Fund was initiated and established by CCB International (CCBI), with the first-phase scale of 500 million yuan. This fund is focused on the investment of healthcare startups in the early and growth stage.